Impact of depressive symptoms on motivation in persons with post-COVID-19 condition.
West J, Kwan A, Teopiz K, Guo Z, Le G, Badulescu S, Rhee T, Wong S, Cao B, Ho R, Rosenblat J, Mansur R, Phan L, Subramaniapillai M, McIntyre R. Impact of depressive symptoms on motivation in persons with post-COVID-19 condition. CNS Spectrums 2024, 1-5. PMID: 39655430, DOI: 10.1017/s1092852924000440.Peer-Reviewed Original ResearchDepressive symptomsMotivational deficitsPost hoc analysisQuick Inventory of Depressive Symptomatology-Self ReportInventory of Depressive Symptomatology-Self ReportQIDS-SR-16Impact of depressive symptomsDepressive symptom severityPost-COVID-19 conditionPost-hocMotivational impairmentsCognitive symptomsSymptom severityMotivational systemsMedical/psychiatric conditionsPlacebo-controlled trialCOVID-19 infectionWorld Health OrganizationSystem QuestionnaireDouble-blindAcute SARS-CoV-2 infectionOnset of symptomsHistory of COVID-19 infectionSymptomsPersonsA systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.
Menon T, Lee S, Gong X, Wong S, Le G, Kwan A, Teopiz K, Ho R, Cao B, Rhee T, Jing Zheng Y, Valentino K, Lin K, Vinberg M, Lo H, McIntyre R. A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain. CNS Spectrums 2024, 1-7. PMID: 39582175, DOI: 10.1017/s1092852924000531.Peer-Reviewed Original ResearchPsychiatric medicationsEffects of GLP-1RAsReceptor agonistsEfficacy of GLP-1 receptor agonistsRandomized controlled trialsGLP-1RAsModerate weight changeMitigate weight gainPsychiatric populationsPsychotropic drugsCognitive processesWeight gainClinically meaningful effectGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1 receptor agonistsSystematic reviewPreliminary evidenceGlucose-lowering agentsLong-term safetyWeight changeMeaningful effectEfficacy profilePersonsAbnormal weight